|
2024
|
G/S
|
Pharmaceutical and biological preparations for human use. |
|
|
G/S
|
Pharmaceutical research and development relating to pharmaceutical preparations for human use. |
|
|
Invention
|
Serially-connectable drug modules for combinatorial drug delivery device.
A combinatorial drug d... |
|
|
Invention
|
Triazolopyridinyl compounds as kinase inhibitors.
Compounds having formula (I), and enantiomers,... |
|
|
Invention
|
Substituted pyridopyrimidinonyl compounds useful as t cell activators.
Disclosed are compounds o... |
|
|
Invention
|
Biaryl kinase inhibitors.
The present disclosure is generally directed to compounds which can in... |
|
|
Invention
|
Kras inhibitors. The present disclosure provides KRAS inhibitors. Methods of treating cancers usi... |
|
|
Invention
|
Lag-3 antagonist therapy for lung cancer.
The disclosure provides a method of treating a human s... |
|
|
Invention
|
Pyridinyl substituted oxoisoindoline compounds.
Disclosed are compounds of Formula (I):
Disclo... |
|
|
Invention
|
Substituted oxoisoindolinyl piperidine-2,6-dione compound as anticancer agent. Disclosed is a com... |
|
|
Invention
|
Near real time sialic acid quantitation of glycoproteins. Systems and methods for the automatic q... |
|
|
Invention
|
Biomarkers and methods of treatment of follicular lymphoma. Provided herein are methods and kits ... |
|
|
Invention
|
Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound. Disclosed is a compound of... |
|
|
Invention
|
Substituted oxazolone compound for decreasing levels of ikzf1-4 proteins. Disclosed is a compound... |
|
|
Invention
|
Ionizable lipids.
The application relates to ionizable lipids. The formulations of ionizable lip... |
|
|
Invention
|
Ionizable lipids. The application relates to ionizable lipids. The formulations of ionizable lipi... |
|
|
Invention
|
H- pyrido[3,2-2β]indole-7-methanol. HSHHbb]indole-7-methanol. Characterization data for the cryst... |
|
|
Invention
|
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling.
The disclosure provides a method for im... |
|
|
Invention
|
Substituted nitrogen containing compounds.
Disclosed are compounds of Formula (I)
Disclosed ar... |
|
|
Invention
|
Substituted phenyl oxazolone compounds. Disclosed are compounds of Formula (I): or stereoisomers,... |
|
|
G/S
|
Pharmaceutical and biological preparations for human use. |
|
|
Invention
|
Use of milvexian for treating or preventing adverse cerebrovascular events or adverse cardiovascu... |
|
|
Invention
|
Use of milvexian in the treatment and prevention of thrombotic conditions in patients with atrial... |
|
|
Invention
|
Use of milvexian in the treatment and prevention of thrombotic conditions in patients with cardio... |
|
|
Invention
|
Antibodies to cd40.
Provided herein are agonistic antibodies, or antigen binding portions thereo... |
|
|
Invention
|
Pyrrolidinone urea fpr2 agonists. The disclosure relates to compounds of formula I, which are for... |
|
|
Invention
|
Carbocyclic phenylpyrrolidinone urea fpr2 agonists. The disclosure relates to compounds of Formul... |
|
|
Invention
|
Pyrrolidinone urea fpr2 agonists. The disclosure relates to compounds of formula (I), which are f... |
|
|
Invention
|
Pyrazolotriazinecarbonitriles useful as kinase inhibitors. The invention provides compounds of Fo... |
|
|
Invention
|
Use of anti-pd-1 antibody in combination with anti-cd27 antibody in cancer treatment.
This inven... |
|
|
Invention
|
Tumor subtype assessment for cancer therapy. The disclosure provides a method of identifying or t... |
|
|
Invention
|
Pharmaceutical compositions for improving oral bioavailability. In accordance with the present di... |
|
|
Invention
|
Compounds and compositions for selective degradation of engineered proteins.
Provided herein are... |
|
|
Invention
|
Antibodies against il-7r alpha subunit and uses thereof.
Provided herein are antibodies that bin... |
|
2023
|
Invention
|
Fibronectin based scaffold domain proteins that bind to myostatin.
The present invention relates... |
|
2022
|
Invention
|
Rxfp1 agonists.
The disclosure relates to compounds of Formula (I), which are RXFP1 receptor ago... |
|
|
Invention
|
Lag-3 antagonist therapy for hematological cancer.
The disclosure provides a method of treating ... |
|
|
Invention
|
Methods for determining responsiveness to tyk2 inhibitors.
Disclosed are methods of treating pso... |
|
|
Invention
|
Methods of treating hair-loss disorders with tyk2 inhibitors.
Methods of preventing or treating ... |
|
|
Invention
|
Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant ... |
|
|
Invention
|
Compound useful for pet-imaging of bruton’s tyrosine kinase.
Disclosed is a compound of Formula ... |
|
|
Invention
|
Crystal forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3- (1-methyl-1h-1,2,4-triazol-3-yl)phe... |
|
|
Invention
|
Tricyclic fused pyrimidine compounds for use as her2 inhibitors.
Provided herein are tricyclic f... |
|
|
Invention
|
High-affinity supramolecular polymers for binding-triggered antibody precipitation and purificati... |
|
|
Invention
|
Macrocyclic immunomodulators.
In accordance with the present disclosure, macrocyclic compounds h... |
|
|
Invention
|
Drug cartridge, drug delivery device, and methods for preparing thereof.
In one aspect, a drug d... |
|
|
Invention
|
Lactone and lactam containing compounds useful as immunomodulators.
The present disclosure gener... |
|
|
Invention
|
Kras g12d inhibitors.
The present disclosure relates to KRAS inhibitors. Methods of treating can... |
|
2021
|
Invention
|
Fusion proteins for the treatment of disease.
Disclosed herein are methods of treating a disease... |
|
|
Invention
|
Dosage forms for tyk2 inhibitors comprising swellable cores.
A swellable core dosage form compri... |
|
2020
|
Invention
|
Dual capture method for analysis of antibody-drug conjugates.
A method for analyzing whether, an... |
